Pertuzumab and Trastuzumab

Phesgo

賀雙妥皮下注射劑

600mg+600mg/10ml/vial

04. ANTINEOPLASTIC AGENTS; ;

04.05. MONOCLONAL ANTIBODIES;;

Anti-HER2

標靶藥物

X 動物或人體的試驗中或使用經驗發現對胎兒有害，而造成的傷害明顯大於可能的益處。

Unknown

SC(Alternate the injection site between the left and right thigh)
Breast cancer
Initial loading dose: Pertuzumab 1200mg/trastuzumab 600mg initially, followed 3 weeks later by maintenance dosing. Maintenance dosing: Pertuzumab 600mg/trastuzumab 600mg once every 3 weeks. Following surgery, continue pertuzumab/trastuzumab to complete 1 year of treatment (up to 18 cycles) or until disease progression or unacceptable toxicity, whichever occurs first.
Conversion to pertuzumab/trastuzumab/hyaluronidase (SC) from IV pertuzumab and trastuzumab
If <6 weeks since the last IV pertuzumab and trastuzumab dose: SC Administer maintenance dose of pertuzumab 600mg/trastuzumab 600mg and then every 3 weeks.
If ≥6 weeks since the last IV pertuzumab and trastuzumab dose: SC Administer initial dose of pertuzumab 1200mg/trastuzumab 600mg, followed 3 weeks later by maintenance dosing of pertuzumab 600mg/trastuzumab 600mg once every 3 weeks.

Anemia, increased serum creatinine, alopecia, nausea, vomiting

對Pertuzumab或Trastuzumab或玻尿酸酶(hyaluronidase)或任何賦形劑過敏的病人

1.藥品須冷藏於2-8℃
2.藥品抽至針筒未立即施打，於冷藏可保存24小時或室溫保存4小時。
3.限皮下注射；注射部位僅應在左右側大腿之間輪換。
4.治療期間及最後一劑治療後7個月內應使用有效避孕措施。

建立者

103617

建立時間

2024-08-14 09:03:26

維護者

103617

維護時間

2024-08-14 09:08:15